口腔颌面BRONJ相关认识与进展

帅 张(呼和浩特市口腔医院，中国)
亚婷 刘(呼和浩特市口腔医院，中国)
学敏 吕(内蒙古自治区人民医院，中国)
文达 贾(内蒙古自治区人民医院，中国)
捷 及(呼和浩特市口腔医院，中国)

摘要

近年来，由于中国人口预期寿命的增加及老年人比例的上升，骨量相对减少和患骨质疏松症的病例数也在相应增加，双膦酸盐类药物的应用主要为了降低长期癌症治疗或骨质疏松症导致的骨质流失以及恶性骨病患者骨骼并发症的风险，同样也适用于其他代谢性骨病。双膦酸盐相关颌骨坏死（Bisphosphonate-related osteonecrosis of the jaw，BRONJ）是长期应用双膦酸盐类药物（Bisphosphonates，BPs）的不良反应，目前，有许多关于BRONJ的治疗方案、指南和建议，对于多数患者来说，保守治疗方法包括用最小的局部干预和良好的伤口护理，防止感染的进一步发展，同时积极的控制疼痛，但局部坏死骨的根治性切除与重建已然成为重要的临床治疗方案。论文从BRONJ的相关发病机制、临床诊断、风险因素、治疗方案、预防策略几个方面作一综述。

关键词

骨质疏松；双磷酸盐类药物；颌骨坏死；骨切除

参考

Ferreira Jr LH Jr, Mendonça Jr KD Jr, Chaves de Souza J, Soares Dos Reis DC, do Carmo Faleiros Veloso Guedes C, de Souza Castro Filice L, Bruzadelli Macedo S, Soares Rocha F. Bisphosphonate-associated osteonecrosis of the jaw. Minerva Dent Oral Sci,2021,70(1):49-57.

Gkouveris I. Hadaya D. Soundia A. et al. Vasculature submucosal changes at early stages of osteonecrosis of the jaw (ONJ). Bone,2019(123):234.

Gavaldá C, Bagán JV. Concept, diagnosis and classification of bisphosphonate-associated osteonecrosis of the jaws. A review of the literature. Med Oral Patol Oral Cir Bucal. 2016 May 1;21(3):e260-270.

True HD, Ricks RG, Smith JA. Denosumab and bisphosphonate associated bilateral osteonecrosis of the external auditory canal. BMJ Case Rep,2021,14(6):e241203.

Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg,2007,65(3):369-376.

赵悦涛.双膦酸盐类药物性颌骨坏死的发病机制、临床表现、特殊检查、预防及治疗方法分析[J].中外医疗,2020,39(25):70-72.

Weinstein RS, Roberson PK, Manolagas SC. Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med,2009,360(1):53-62.

López-D’alessandro E, Mardenlli F, Paz M. Oral bisphosphonate-associated osteonecrosis of maxillary bone: A review of 18 cases. J Clin Exp Dent. 2014 Dec 1;6(5):e530-534.

Kizub DA, Miao J, Schubert MM, Paterson AHG, Clemons M, Dees EC, Ingle JN, Falkson CI, Barlow WE, Hortobagyi GN, Gralow JR. Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307). Support Care Cancer. 2021,29(5):2509-2517.

Kanwar N, Bakr MM, Meer M, Siddiqi A. Emerging therapies with potential risks of medicine-related osteonecrosis of the jaw: a review of the literature. Br Dent J. 2020,228(11):886-892.

李萌宇,王绍义.双膦酸盐相关性颌骨坏死的发生机制与风险评估[J].口腔医学,2017,37(9):849-853.

殷学民,王方圆.双膦酸盐性颌骨坏死的临床诊断与治疗[J].口腔疾病防治,2017,25(3):137-142.

Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons’ Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update. J Oral Maxillofac Surg. 2022 May;80(5):920-943.

Nicolatou-Galitis O, Schiødt M, Mendes RA, Ripamonti C, Hope S, Drudge-Coates L, Niepel D, Van den Wyngaert T. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. Oral Surg Oral Med Oral Pathol Oral Radiol,2019,127(2):117-135.

Yarom N, Shapiro CL, Peterson DE, Van Poznak CH, et al. Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline. J Clin Oncol,2019,37(25):2270-2290.

DOI: http://dx.doi.org/10.12345/yzlcyxzz.v6i11.14531